➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Baxter
Harvard Business School
Medtronic
AstraZeneca

Last Updated: August 14, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for NBI-98854

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for NBI-98854?

NBI-98854 is an investigational drug.

There have been 38 clinical trials for NBI-98854. The most recent clinical trial was a Phase 3 trial, which was initiated on September 14th 2018.

The most common disease conditions in clinical trials are Dyskinesias, Tourette Syndrome, and Syndrome. The leading clinical trial sponsors are Neurocrine Biosciences, AbbVie (prior sponsor, Abbott), and Huntington Study Group.

There are seven US patents protecting this investigational drug and twenty-seven international patents.

Recent Clinical Trials for NBI-98854
TitleSponsorPhase
Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington DiseaseHuntington Study GroupPhase 3
Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington DiseaseNeurocrine BiosciencesPhase 3
Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal HyperplasiaNeurocrine BiosciencesPhase 3

See all NBI-98854 clinical trials

Clinical Trial Summary for NBI-98854

Top disease conditions for NBI-98854
Top clinical trial sponsors for NBI-98854

See all NBI-98854 clinical trials

US Patents for NBI-98854

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
NBI-98854   Start Trial Pharmaceutical formulations Auspex Pharmaceuticals, Inc. (La Jolla, CA)   Start Trial
NBI-98854   Start Trial Pharmaceutical compounds Biovail Laboratories International (Barbados) S.R.L. (Christ Church, BB)   Start Trial
NBI-98854   Start Trial Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 Auspex Pharmaceuticals, Inc. (La Jolla, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Baxter
Harvard Business School
Medtronic
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.